Q-omics provides the consensus-scored KIR2DL3 profile across patient tissues and cancer cell-line models. KIR2DL3 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, KIR2DL3 is differentially expressed in 8, with the highest sampling consensus in KIRC. Additionally, KIR2DL3 RNA expression shows 8,967 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight SKCM, KIRC, and TGCT as cancer lineages where KIR2DL3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KIR2DL3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KIR2DL3 survival associations across molecular data types. KIR2DL3 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KIR2DL3 RNA expression–survival associations across cancer types. High KIR2DL3 expression shows unfavorable associations in UVM and KIRP, but favorable associations in SKCM, BLCA, ACC and ESCA. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for KIR2DL3 RNA expression.
This table summarizes KIR2DL3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for KIR2DL3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KIR2DL3 shows lower tumor expression in LUAD, LUSC and PAAD and higher tumor expression in KIRC, HNSC and STAD. The KIRC box plot shows higher KIR2DL3 RNA expression in tumor versus normal tissue (log2 FC = +0.312, t-test p < 0.001).
This table shows molecular features associated with KIR2DL3 in patient tissues and cancer cell lines. In patient samples, KIR2DL3 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, KIR2DL3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and OVARY.
